These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38047588)

  • 1. The Value of Liver Biopsy and Histology in Liver Disease Diagnosis and Patient Care-a Pragmatic Prospective Clinical Practice Study.
    Khalifa A; Rockey DC
    J Clin Gastroenterol; 2024 Oct; 58(9):912-916. PubMed ID: 38047588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.
    Pavlov CS; Casazza G; Nikolova D; Tsochatzis E; Burroughs AK; Ivashkin VT; Gluud C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010542. PubMed ID: 25612182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
    Kwo PY; Cohen SM; Lim JK
    Am J Gastroenterol; 2017 Jan; 112(1):18-35. PubMed ID: 27995906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?
    Sakhuja P
    World J Gastroenterol; 2014 Nov; 20(44):16474-9. PubMed ID: 25469015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study.
    Haque M; Robinson C; Owen D; Yoshida EM; Harris A
    Ann Hepatol; 2010; 9(3):289-93. PubMed ID: 20720270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
    Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
    Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 10. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
    Larrey D; Meunier L; Ursic-Bedoya J
    Ann Hepatol; 2017; 16(4):487-489. PubMed ID: 28612749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The accuracy of the clinical diagnosis in acute hepatitis and alcoholic liver disease. Clinical versus morphological diagnosis.
    Kryger P; Schlichting P; Dietrichson O; Juhl E
    Scand J Gastroenterol; 1983 Jul; 18(5):691-6. PubMed ID: 6675190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
    Naveau S; Raynard B; Ratziu V; Abella A; Imbert-Bismut F; Messous D; Beuzen F; Capron F; Thabut D; Munteanu M; Chaput JC; Poynard T
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):167-74. PubMed ID: 15704051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data.
    Gaia S; Campion D; Evangelista A; Spandre M; Cosso L; Brunello F; Ciccone G; Bugianesi E; Rizzetto M
    Liver Int; 2015 Aug; 35(8):2027-35. PubMed ID: 25495478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.
    Buzzetti E; Petta S; Manuguerra R; Luong TV; Cabibi D; Corradini E; Craxì A; Pinzani M; Tsochatzis E; Pietrangelo A
    Liver Int; 2019 Jul; 39(7):1325-1334. PubMed ID: 30851216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
    McPherson S; Dyson JK; Jopson L; Masson S; Patel P; Anstee QM
    Aliment Pharmacol Ther; 2024 Jul; 60(2):267-273. PubMed ID: 38860621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.